Introduction
============

Biofilms are surface-attached microbial communities surrounded by a polymeric matrix, which protects them from the external environment. This complex structure confers to the bacteria a high resistance to antibiotics, disinfectants and to the host, an immune system response ([@B26], [@B26]). The ability to develop a biofilm is one of the major virulence factors in many pathogenic bacteria, while it is a key factor for colonization in opportunistic bacteria. *Staphylococcus epidermidis* is a prominent example of a bacterial species with a pathogenicity associated to the biofilm formation on medical devices ([@B53]), being the most common cause of bacteremia in immune-compromised patients ([@B52]). In addition, methicillin resistant strains (MRSE) carrying the staphylococcal cassette chromosome *mec* (SCC*mec*), are widely spread within hospitals ([@B30]), and provide a reservoir of resistance that might be transferred to *Staphylococcus aureus* ([@B49]), also a frequent cause of nosocomial infections. *S. aureus* encodes a number of virulence factors that enable to infect host tissues ([@B38]). In addition, methicillin-resistant *S. aureus* (MRSA) isolates, resistant to all available penicillins and other β-lactam antibiotics, have rapidly disseminated beyond clinical settings among general population ([@B13]) and livestock ([@B51]).

Extracellular material of staphylococcal biofilms is a complex combination of polysaccharides, teichoic acids, proteins and DNA. The polysaccharide intercellular adhesin (PIA/PNAG) is a poly-β-1,6-*N*-acetyl glucosamine, which production is dependent on the presence of the operon icaADBC ([@B41]). However, staphylococcal strains with a PIA/PNAG-independent biofilm were also identified. In this case, the extracellular matrix is based on the presence of adhesive proteins such as Aap, Embp, Bhp, and Bap ([@B29]; [@B10]; [@B64]; [@B7]). The presence of teichoic acids in staphylococcal species enhances adhesion of bacterial cells to fibronectin, increasing their pathogenicity ([@B28]; [@B62]). In addition, a number of microbial surface components recognizing adhesive matrix molecules (MSCRAMMs) are able to interact with the host matrix proteins ([@B50]). Finally, the modulation of the extracellular genomic DNA (eDNA) release and degradation was shown as an important factor in biofilm maturation ([@B42]).

Due to the importance of biofilms in hospital settings, several approaches to prevent and remove them have been assayed. New materials were designed by coating their surface with different antimicrobials, like bacteriocins and essential oils, which caused a reduction in biomass and viability of bacteria in biofilms ([@B46], [@B45]). Other changes in physicochemical properties of biomaterial surfaces resulted in reduction of bacterial adhesion and further biofilm formation ([@B59]). Additional strategies were focused on small molecules that interfere with the expression of virulence genes including those necessary for biofilm formation ([@B40]). Finally, it is noteworthy that previously formed biofilms can be removed by degrading the extracellular matrix or by killing the bacteria inside the structure. Alternatives to antibiotics for killing bacteria and biofilm removal include bacteriocins ([@B54]), bacteriophages ([@B5]; [@B23], [@B25]) and endolysins ([@B15]; [@B55]; [@B24]). However, to eradicate the biofilm structure a successful degradation of extracellular matrix is required. Regarding this, PIA-degrading enzymes like dispersin B ([@B35]) and bacteriophage-encoded polysaccharide depolymerase proteins ([@B8]) have been proposed.

We have previously identified and characterized two bacteriophages infecting *S. epidermidis*, vB_SepiS-phiIPLA5 and vB_SepiS-phiIPLA7, which exhibit plaques surrounded by an increasing halo zone indicative of the presence of polysaccharide depolymerase activity ([@B22]). Genomic characterization of phage vB_SepiS-phiIPLA7 showed a protein (gp18, 98.5 kDa) located in the structural region containing two catalytic domains. A putative pectin lyase domain was identified at the amino-terminal part of the protein, and a putative peptidase domain at the C-terminus. It was suggested that the anti-biofilm activity showed by phage vB_SepiS-phiIPLA7 may be attributed to this protein ([@B23]). In the present work, protein gp18 named Dpo7, was overexpressed in *E. coli* and purified. The polysaccharide depolymerase activity of Dpo7 was confirmed against *S. epidermidis* and *S. aureus* biofilms.

Materials and Methods {#s1}
=====================

Bacterial Strains and Growth Conditions
---------------------------------------

Ten different *S. epidermidis* strains and two *S. aureus* strains were used in this study (**Table [1](#T1){ref-type="table"}**). All bacteria were isolated in Baird--Parker (BP) agar and routinely cultured in TSB broth (Tryptic Soy Broth, Scharlau, Barcelona, Spain) at 37°C with shaking or in TSB plates containing 2% (w/v) bacteriological agar (TSA). *E. coli* transformants were selected on LB medium (1% tryptone, 0.5% yeast extract, 1% NaCl) supplemented with 2% (w/v) bacteriological agar and 100 μg ml^-1^ ampicillin at 37°C.

###### 

Strains used in this study.

                     Strain    Reference
  ------------------ --------- -----------
  *S. epidermidis*   F12       [@B14]
                     B         
                     DH3LIK    
                     YLIC13    
                     Z2LDC14   
                     DG2n      
                     ASLD1     
                     LO5081    
                     LV5RB3    
                     LO5RB1    
  *S. aureus*        15981     [@B61]
                     V329      [@B10]

Cloning and Overexpression of Dpo7
----------------------------------

The codon usage of the *orf18* gene, encoding Dpo7 (GenBank accession number YP_006561180.1) from phage vB_SepiS-phiIPLA7 was optimized based on *E. coli* codon usage by the OptimumGene^TM^ Codon Optimization Technology. Additionally, *Nde*I and *Xho*I restriction sites were added at the 5′ and 3′ ends of the sequence, respectively. The optimized sequence was synthesized and cloned into pUC57 vector by GenScript (Township, NJ, USA). Afterward, a *Nde*I-*Xho*I fragment containing the *orf18* gene was released from pUC57 and sub-cloned into pET21a(+) vector (EMD Biosciences, San Diego, CA, USA), which introduces a C-terminal 6 His-tag. The construct (pET21a-*dpo7*) was verified by DNA sequencing using vector-specific primers (T7 promoter: 5′-TAATACGACTCACTATAGGG-3′ and T7 terminator 5′-GCTAGTTATTGCTCAGCGG-3′, Eurogentec, Madrid, Spain) and two internal primers (5′-TCAGAAAGATTCCACGAAGG-3′ and 5′-TAATGGCCATGTGAGCATC-3′, Eurogentec, Madrid, Spain).

The plasmid pET21a-*dpo7* was electroporated in *E. coli* BL21 (DE3) pLysS (Invitrogen Corporation, Gent, Belgium) and protein expression was carried out as described previously ([@B47]) with 1 mM of IPTG for 16 h at 16°C. Five hundred milliliter culture cells were pelleted, suspended in 10 ml lysis buffer (20 mM NaH~2~PO~4~, 500 mM NaCl, 10 mM imidazole, pH 7.4) and frozen/thawed three times at -80°C. Sonication was carried out afterward 15 × 5 s pulses with 15 s recovery on ice and centrifuged at 10,000 × *g*. The supernatant containing the protein was purified using the His GraviTrap column kit (GE Healthcare Life Sciences, Buckinghamshire, UK) following the supplier's recommendations. Wash buffer and lysis buffer were composed of 20 mM NaH~2~PO~4~, 500 mM of NaCl, pH 7.4 with 50 or 500 mM imidazole, respectively. Protein purity was estimated by SDS-PAGE and the predicted amino acid sequence was confirmed by mass spectrometry (MALDI-TOF/TOF) as previously described ([@B19]). Protein amount was quantified by the Quick Start Bradford Protein Assay (BioRad, Hercules, CA, USA). Prior to the activity assays, the purified Dpo7 was dialyzed for 16 h against PBS buffer (137 mM NaCl 2.7 mM KCl 10 mM Na~2~HPO~4~ 2 mM KH~2~PO~4~; pH 7.4).

Biofilm Assays
--------------

Biofilms of staphylococcal strains were grown into a TC Microwell 96U w/lid nunclon D SI plates (Thermo Scientific, NUNC, Madrid, Spain). Overnight cultures were diluted in TSBg \[TSB supplemented with 0.25% w/v [D]{.smallcaps}-(+)-glucose\] up to 10^6^ CFU/ml and 200 μl were poured into each well and incubated for 24 h at 37°C. Wells were washed twice with sterile phosphate-buffered saline (PBS buffer) (137 mM NaCl, 2.7 mM KCl, 10 mM Na~2~HPO~4~ and 2 mM KH~2~PO~4~; pH 7.4). After treatment of biofilms (see below), cultivable bacteria released in the supernatant were counted by plating on TSA serial dilutions. Moreover, cultivable adhered bacteria were determined by scratching twice with a sterile swab and then immersed into 9 ml of PBS buffer followed by a vigorous shaking for 1 min. Finally, several decimal dilutions were plated onto TSA and incubated at 37°C. Biomass quantification of biofilm adhered to the surface of wells was carried out as previously described ([@B48]). Briefly, wells were treated with crystal violet (0.1% w/v) for 15 min, followed by a gentle wash with water and de-staining in acetic acid (33% v/v). Finally, absorbance was measured at 595 nm. To determine the matrix composition, the biofilms were washed with PBS and then treated for 1 h at 37°C with a solution of 10 mM sodium metaperiodate in 50 mM sodium acetate buffer (pH 4.5) (to disrupt the extracellular polysaccharides), with 100 mg/ml of proteinase K (Sigma, Madrid, Spain) in 20 mM Tris HCl (pH 7.5) and 100 mM NaCl, or with 100 mg/ml of DNaseI (Sigma, Madrid, Spain) in 150 mM of NaCl and 1 mM CaCl~2~ ([@B35]; [@B27]). After treatments, the biofilms were washed with water, stained with crystal violet, and the absorbance measured as described above. All assays were performed using four biological replicates.

Characterization of Dpo7 Activity
---------------------------------

To determine the optimal conditions for Dpo7 activity, different concentrations of the protein (0--1.5 μM) or PBS buffer for control purposes, were added to 24 h-preformed biofilms of *S. epidermidis* F12, and incubated for different times (30 min -- 24 h) at temperatures ranging from 22 to 37°C. Biofilm removal was quantified by enumeration of cultivable bacteria and crystal violet staining (see above).

The activity of the protein was also tested against the biofilms formed by other staphylococcal strains using 0.15 μM of Dpo7 for 3 h at 37°C. All experiments were performed in triplicate.

The ability of Dpo7 to prevent biofilm formation was also tested using a conventional broth microdilution technique. Two-fold dilutions of Dpo7 (0--1.5 μM) in TSBg were added to TC Microwell 96U w/lid nunclon D SI plates (Thermo Scientific, NUNC, Madrid, Spain) in order to test biofilm formation and to 96-Well Microtiter^TM^ Microplates (Thermo Scientific, NUNC, Madrid, Spain) to assess planktonic bacterial growth. Each well was inoculated with 10^6^ CFU/well of bacteria. Plates were incubated at 37°C for 24 h. Biofilm formation was quantified by crystal violet staining and measuring the absorbance at 595 nm. Planktonic growth was determined by measuring the absorbance at 600 nm of each supernatant.

Dpo7 activity against extracellular material was assessed by using exponential cultures (OD~600~ = 0.6) of *S. epidermidis* F12 in TSBg. Cells were suspended in PBS buffer containing 0.15 μM of Dpo7 and incubated for 3 h at 37°C. Three microliter of the cells diluted in 10 μl of 1% Congo red aqueous solution (Sigma--Aldrich, St. Louis, MO, USA) were spread onto a glass slide and air-dried. To visualize the extracellular material, staining with Maneval's solution was performed as previously described ([@B9]).

Quantification of lytic activity of Dpo7 was tested against live *S. epidermidis* F12 cells prepared as previously described ([@B4]), using the turbidity reduction assay ([@B47]).

The pH stability of the protein Dpo7 was tested by dilution (1.5 μM) into the Britton--Robinson pH universal buffer (150 mM KCl, 10 mM KH~2~PO~4~, 10 mM sodium citrate, 10 mM H~3~BO~3~, adjusted within a pH 3--11 range, and subsequent maintenance at room temperature for 1 h. The protein was then diluted 10-fold in PBS buffer. For control purposes, Britton--Robinson buffer was diluted 10-fold in PBS buffer. Similarly, the temperature stability was examined after incubation of 0.15 μM of Dpo7 in PBS buffer for 30 min at different temperatures (ranging from 40 to 90°C). The activity of the protein after these treatments was tested against 24 h-biofilms of *S. epidermidis* F12 as indicated above.

Statistical Analysis
--------------------

A one-way analysis of variance (ANOVA) and the LSD test was carried out to establish any significant differences regarding the adhered cells and cells number in the supernatant and biomass between the control and the treated biofilms. The differences were expressed as the mean ± standard error and the level of significance was established at *P \<* 0.05 (SPSS11.0 Software for windows; Chicago, IL, USA).

Results
=======

Dpo7 is Able to Remove *S. epidermidis* Extracellular Material in Both Biofilms and Planktonic Cells
----------------------------------------------------------------------------------------------------

To determine the activity of the recombinant protein Dpo7, a synthetic gene with optimized codons was used for expression in *E. coli* BL21 (DE3) pLysS as an N-terminal 6×-His-tagged fusion, allowing purification by immobilized metal chelate affinity chromatography. The purity of the protein was estimated to be 95% as assessed by SDS-PAGE analysis (**Figure [1](#F1){ref-type="fig"}**). A main band of about 98 kDa corresponding with the molecular weight of Dpo7 was observed. A minor additional band (32 kDa) was identified by mass-spectrometry as a degradation product of Dpo7. Stocks of about 15 μM of protein were routinely obtained in these conditions.

![**Purification of the recombinant exopolysaccharide depolymerase Dpo7 from *Escherichia coli* BL21(DE3) pLys pET21a-*dpo7*.** L: Standard molecular weight marker in kDa (Low Range Molecular Weight SDS-PAGE Standards, BioRad); Fraction eluted from nickel affinity chromatography containing purified Dpo7. Bands indicated with a black arrow were identified by mass spectrometry.](fmicb-06-01315-g001){#F1}

The activity of the recombinant Dpo7 was characterized by treatment of 24 h-biofilms of the strain *S. epidermidis* F12 with different concentrations of Dpo7 for 3 h at 37°C (**Figure [2A](#F2){ref-type="fig"}**). Total biomass that remained attached after the Dpo7 treatment was quantified by crystal violet staining. The maximum biofilm disruption (43%) was obtained with 0.075 μM and higher concentrations (up to 1.5 μM) did not improve significantly this result (*P* \< 0.05). Moreover, the number of cultivable bacteria was also determined after Dpo7 treatment. The maximum removal of attached cells (about 1 log unit; 92% of the total) was obtained treating the biofilms with 0.15 μM of the recombinant protein. This value correlates with the increase in the number of cells in the supernatant (**Figure [2A](#F2){ref-type="fig"}**) but the total cell number (adhered plus planktonic) remained constant (data not shown), indicating that biofilm-associated cells were released to the planktonic state without any lytic activity of Dpo7. A turbidity reduction assay confirmed the absence of lytic activity in Dpo7. There were no statistical differences between the control and the treated cells (data not shown). These results support the hypothesis that the activity of Dpo7 is related with the degradation of the extracellular material that surrounds the bacteria inside the biofilm rather than lysis of the cells.

![**Activity of Dpo7 against 24 h-biofilms of *Staphylococcus epidermidis* F12 in PBS buffer at 37°C.** Biofilm disruption was determined using **(A)** different concentrations of Dpo7 (μM) for 3 h at 37°C and **(B)** 0.15 μM of Dpo7 throughout time ranging 30 min to 6 h. Total attached biomass was measured by crystal violet staining after treatment and expressed as *A~*595*~* units (▲); Adhered cultivable bacteria (●) and supernatant cultivable bacteria (■) are expressed as Log (CFU/well). Each value corresponds to the mean ± standard deviation of three independent experiments.](fmicb-06-01315-g002){#F2}

Once the Dpo7 minimum concentration to disrupt 50% of the biofilm was established, an assay with different time exposures was carried out at 37°C (**Figure [2B](#F2){ref-type="fig"}**). For control purposes, the number of cultivable bacteria and biomass staining were recorded in biofilms treated only with PBS buffer for each time, but no differences were observed during the assay. The results showed that the protein was active and most of biofilm matrix degradation took place within the first 30 min. The minimum adhered cells and the maximum cells in the supernatants were also detected 30 min after treatment, remaining stable until the end of the exposure (**Figure [2B](#F2){ref-type="fig"}**). Longer times of incubation (until 24 h) did not change these results.

The optimum parameters for Dpo7 activity were determined by incubation at several temperatures (22, 32, and 37°C). Dpo7 was active in all temperatures tested with increasing activity at increasing temperature (25, 30, and 44% of biomass was removed at 22, 32, and 37°C, respectively). Dpo7 was found to be quite thermostable as heat treatments up to temperatures of 70°C did not significantly affect the enzymatic activity (**Figure [3A](#F3){ref-type="fig"}**). Dpo7 was also stable in a range of pH from 6 to 8 (**Figure [3B](#F3){ref-type="fig"}**). After 90 days of storage a 4°C, no decrease of activity was observed (data not shown).

![**Temperature **(A)** and pH **(B)** stability of Dpo7.** Temperature stability was tested by incubation of Dpo7 (0.15 μM) for 30 min and pH stability after maintenance at room temperature for 1 h. C: control biofilm of *S. epidermidis* F12 without Dpo7 treatment; NT: activity of Dpo7 at pH 7.4 without temperature treatment. Values represent the mean ± standard deviation of three independent experiments. Bars having an asterisk are statistically significant different from the control and bars with a lower case 'a' indicate a statistically significant difference between the biofilm treatment with standard Dpo7 and the activity after thermal or pH treatment (ANOVA; *P* \< 0.05).](fmicb-06-01315-g003){#F3}

A qualitative approach about the potential of Dpo7 to degrade the extracellular material formed by *S. epidermidis* F12 in liquid cultures was obtained by staining and optical microscopy (**Figure [4](#F4){ref-type="fig"}**). Cells grown to exponential phase were incubated with 0.15 μM of Dpo7 for 3 h at 37°C. Microscopic analysis showed that non-treated cells are closely associated into small clusters surrounded by a thin layer of negatively stained capsular material (**Figure [4A](#F4){ref-type="fig"}**). After treatment with exopolysaccharide (EPS) depolymerase Dpo7, the capsule is generally thinner or drastically disrupted, and remaining capsular material devoid of bacteria can be observed (**Figure [4B](#F4){ref-type="fig"}**).

![**Maneval's staining of extracellular material in exponential-phase cultures of *S. epidermidis* F12 **(A)** before treatment and **(B)** after treatment with 0.15 μM of Dpo7 for 3 h at 37°C.** A magnification of the figure allows for the comparison of the presence/absence of polysaccharide matrix represented by a white halo surrounding the cell.](fmicb-06-01315-g004){#F4}

The Exopolysaccharide is the Main Substrate of Dpo7
---------------------------------------------------

To determine the specificity of Dpo7 for the components of *S. epidermidis* biofilms, we tested its activity against biofilms with different biochemical matrix compositions. Our *S. epidermidis* and *S. aureus* strains collection was tested for matrix composition by using treatment with either NaIO~4~, proteinase K and DNaseI, specific for exopolysaccharidic, proteinaceous and DNA matrix, respectively. An estimation of the matrix composition was made as function of the percentage of biofilm removal after treatments. The results showed that all *S. epidermidis* strains tested produced a matrix composed mainly of EPS as the highest percentage of biofilm removal was obtained after treatment with NaIO~4~. Strains *S. aureus* 15981 and *S. aureus* V329 formed EPS and proteinaceous biofilms, respectively (**Table [2](#T2){ref-type="table"}**). Dpo7 assays against 24 h-biofilms of *S. epidermidis* strains showed a significant reduction in adhered cells from biofilms containing an EPS matrix (**Figure [5A](#F5){ref-type="fig"}**). The decrease ranged from 1 log-unit in the biofilm formed by *S. epidermidis* LO5RB1 to 2.3 log-units in *S. epidermidis* DH3LIK biofilm. Moreover, an increase in the number of cells was observed in the supernatant (data not shown). As expected, the number of adhered cells in *S. aureus* V329 biofilms was not reduced due to its proteinaceous biofilm matrix but a clear reduction was observed in *S. aureus* 15981 (**Figure [5A](#F5){ref-type="fig"}**). These results were confirmed by staining the total biomass with crystal violet. Dpo7 activity against EPS biofilms showed a reduction of biomass ranging from 31% in *S. epidermidis* ASLD1 to 75% in *S. epidermidis* LO5081, remaining unaffected in *S. aureus* V329 (**Figure [5B](#F5){ref-type="fig"}**).

###### 

Estimation of the extracellular components in biofilms formed by staphylococcal strains through the percentage of biofilm removing after treatment.

                     Strain     \% of removed biofilm                
  ------------------ ---------- ----------------------- ------------ -------------
  *S. epidermidis*   F12        77.7 ± 9.0              1.9 ± 0.3    14 ± 5.9
                     B^∗^       76.2 ± 8.2              2.7 ± 1.4    14.9 ± 3.1
                     DH3LIK     85 ± 3.8                5.9 ± 1.9    6.2 ± 1.2
                     YLIC13     71.8 ± 1.3              8 ± 1.8      22 ± 2.4
                     Z2LDC14    73.4 ± 2.8              7.7 ± 2.7    32.3 ± 5.5
                     DG2n^∗^    75.2 ± 4.6              3.9 ± 1.5    24.7 ± 10.4
                     ASLD1      73.3 ± 5.6              0.5 ± 0.3    24.2 ± 7.1
                     LO5081     81.4 ± 9.6              9.7 ± 3.3    36.6 ± 3.3
                     LV5RB3     76.7 ± 4.2              8.1 ± 7.7    23.1 ± 6.4
                     LO5RB1     86.2 ± 6.0              6.1 ± 2.7    23.1 ± 9.5
  *S. aureus*        15981^∗^   88.7 ± 2.5              3.5 ± 0.9    1.6 ± 0.8
                     V329^∗^    3.2 ± 5.1               88.7 ± 0.1   49.4 ± 2.2

∗

Results published in

Gutiérrez et al. (2014)

.

![**Removal of 24 h *S. epidermidis* and *S. aureus* biofilms after addition of Dpo7 (0.15 μM) for 3 h at 37°C. (A)** Adhered cultivable bacteria and **(B)** crystal violet staining of control biofilms (black) and treated biofilms (white). Means and standard deviations were calculated from three biological replicates. Bars having an asterisk are significantly different from the control (ANOVA; *P* \< 0.05).](fmicb-06-01315-g005){#F5}

Dpo7 Prevents the Biofilm Formation on Polystyrene Surfaces
-----------------------------------------------------------

In addition to the evaluation of Dpo7 to prevent biofilm formation in staphylococcal strains, we tested the effect of the protein on the planktonic growth of the strains. Microwell plates filled with TSBg supplemented with Dpo7 (0--1.5 μM) were inoculated with staphylococcal strains and the growth at 37°C was monitored by DO~600~ after 24 h of incubation. No statistically significant differences were observed between planktonic cultures treated and non-treated with Dpo7 at any assayed concentration. **Figure [6A](#F6){ref-type="fig"}** shows results obtained at 0.15 μM Dpo 7 but higher concentrations (up to 1.5 μM) did not affect planktonic growth.

![**Biofilm growth inhibition in presence of Dpo7 (0.15 μM). (A)** Planktonic growth of the cultures was determined by absorbance measurement at 600 nm after 24 h of incubation at 37°C. **(B)** Percentage of biofilm inhibition was calculated by crystal violet staining of adhered cells after growth of 24 h biofilms. Black bars represent the control values and white bars represent the values of wells treated with Dpo7. Means and standard deviations were calculated from three biological replicates. Bars having an asterisk are significantly different from the control (ANOVA; *P* \< 0.05).](fmicb-06-01315-g006){#F6}

In order to assess the ability of Dpo7 to prevent biofilm formation, staphylococcal strains were also grown in the presence of different concentrations (0--1.5 μM) of Dpo7 and checked for biofilm formation by crystal violet staining. The presence of 0.15 μM of Dpo7 inhibited biofilm formation as total biomass adhered to the polystyrene surface decreased from 27% in *S. epidermidis* LV5RB3 to 85% in *S. epidermidis* Z2LDC14 (**Figure [6B](#F6){ref-type="fig"}**). Higher concentrations of Dpo7 (up to 1.5 μM) did not improve these results (data not shown). However, the presence of the Dpo7 did not affect biofilm formation in the case of *S. epidermidis* B, DG2n, LO5RB1 and *S. aureus* V329 (**Figure [6B](#F6){ref-type="fig"}**).

Discussion
==========

In this study, we have purified a phage-derived EPS depolymerase, Dpo7, which degrades the EPS matrix of *S. epidermidis* and *S. aureus* biofilms. Apart from Dispersin B, an *N*-acetylglucosaminidase enzyme produced by *Aggregatibacter actinomycetemcomitans* ([@B32]), no other enzymes degrading staphylococcal biofilm matrix formed by polysaccharides have been described so far. This finding prompted us to study Dpo7 as a strategy for controlling the colonization and biofilm formation by staphylococcal pathogens. The presence of depolymerases is common among phages, playing a putative role in phage adsorption and infection ([@B9], [@B8]). Similar proteins to Dpo7 are also present in three other *Siphoviridae* phages infecting *S. epidermidis* ([@B11]; [@B23]). All phage EPS depolymerases characterized to date are enzymes that hydrolyze polysaccharides or polysaccharide derivatives and are common constituents of the tail spikes ([@B63]). For instance, phage EPS depolymerases include endorhamnosidases ([@B43]; [@B3]), alginate lyases ([@B21]), endosialidases ([@B33]) and hyaluronidases ([@B57]). Regarding Dpo7, it is reasonable to hypothesize that it is associated to the capsid. Indeed, Dpo7 amino acid sequence showed 99% homology with a pre-neck appendage protein encoded by *S. epidermidis* bacteriophage CNPH82 and high similarity in the tridimensional structure with phi29 gp12 neck protein ([@B23]).

The protein Dpo7 contains a predicted pectin lyase domain, the structure of which is composed of a right-handed β-helix ([@B23]). Proteins containing these repeats are usually enzymes with polysaccharide substrates, and this topology is shared by several proteins, including bacterial pectate lyases, fungal and bacterial galacturonases. Also, the phage tail spike protein HylP1, encoded by l-like phage infecting *Streptococcus pyogenes*, is a hyaluronidase with a similar structure ([@B57]). Our results show that Dpo7 is involved in the degradation of the EPS biofilm matrix of staphylococcal strains. The ability of Dpo7 to disperse polysaccharide staphylococcal preformed biofilms, but not the proteinaceous biofilm formed by the strain *S. aureus* V329 supports this hypothesis. Degradation of proteins associated with *S. aureus* biofilm formation and host--pathogen interaction was previously described by *S. epidermidis* protease Esp ([@B58]).

In spite of the low identity (13%) and similarity (21%) percentages between the amino acid sequences of Dpo7 and DispersinB^®^, the enzymatic activity and the optimum conditions of Dpo7 were similar to those of DispersinB^®^. Of note, the last one has been proved to be effective removing over 85% of the biomass of some staphylococcal biofilms when applying 40 or 50 μg ml^-1^ ([@B34]; [@B32]; [@B60]). The activity of Dpo7 was not dependent on the ability of the strains to form weaker or stronger biofilms but on the nature of the matrix. Indeed, the highest percentage of biofilm removal was obtained against *S. epidermidis* Z2LDC14 and *S. epidermidis* LO5081, which showed a high and a moderate ability to form biofilm, respectively, from among *S. epidermidis* strains. We also observed that concentrations over 0.15 μM did not improve biofilm dispersion even if time of treatment was increased. The maintenance of the biofilm after the treatment could be due to the heterogeneity of the biofilm matrix or to a low diffusion of the protein within the biofilm. In EPS biofilms, although the majority of the extracellular matrix is composed of polysaccharides, interactions with eDNA and proteins should not be discarded ([@B32]) therefore limiting the potential of Dpo7 to remove the biofilm completely. This limitation was also observed when using DispersinB^®^ to remove biofilms formed by *S. pseudintermedius* ([@B60]). The activity of this enzyme was dependent on the proportion of the constituents of the biofilm matrix, which varies with the growth conditions and among the different strains ([@B6]). Moreover, PIA/PNAG molecules do not have a definite structure and are not well-defined substrates, varying in length and charge ([@B41]). It has been demonstrated that the chain length of PIA/PNAG increased the catalytic efficiency of DispersinB^®^ ([@B18]). Similarly, Dpo7 may control EPS staphylococcal biofilms, but its activity could be limited by the nature of the biofilm matrix, requiring the use of combined treatments to completely eradicate the biofilm. Combined treatments of DispersinB^®^ with antibacterials such as triclosan or cefamandole nafate reduced colonization and biofilm formation by *S. aureus, S. epidermidis*, and *E. coli* in coated medical devices ([@B16]; [@B12]). Moreover, the development of an engineered enzymatic bacteriophage (T7) modified to express DispersinB^®^ during infection, enhanced the ability of the phage to reduce biofilms formed by *E. coli* ([@B39]).

The relatively low activity of Dpo7 against extracellular material allows us to speculate about the role of this protein in the viral particle. Dpo7 might be implicated in the access of phage to the bacterial surface without a total disaggregation of the biofilm structure. Moreover, cells susceptible to phage attack should be located in the outer zone of biofilms, where nutrients and oxygen availability allow them to grow actively. Therefore, the biological function of Dpo7 might not be the highly effective degradation of extracellular EPS matrix but to open a local trajectory to enable virion/cell contact.

A major finding of this study was that treatment of polystyrene surfaces with Dpo7 inhibits the colonization by staphylococcal strains. It seems that removal of the extracellular material at the early stages of the culture is sufficient to prevent the adhesion of most strains to the polystyrene surfaces. As deduced from our results, Dpo7 is also able to remove extracellular material from planktonic cells, resulting in the inhibition of biofilm formation. This is in accordance with previous results obtained adding DispersinB^®^ for biofilm prevention of several bacteria specific strains such as *S. epidermidis, E. coli*, or *Yersinia pestis*, which produce polysaccharidic matrixes ([@B31]), and it was also useful to reduce but not completely inhibit biofilm formation of several strains of *S. pseudintermedius* ([@B60]).

All these results in addition to the lack of an antibacterial effect of Dpo7 indicates that this enzyme would be used to remove the extracellular material in staphylococcal strains to reduce their virulence, since it has been shown that *S. epidermidis* mutants deficient in the ability to synthesize PIA/PNAG are avirulent in animal models of infection ([@B56]). Similarly, biofilm production by *S. aureus* is important for high-level virulence in murine models of systemic infection, likely due to protection of cells from host defenses ([@B37]). Thus, Dpo7 may also be considered as an antivirulence compound. Generally, resistance development against antivirulence compounds is expected to be lower than against antibacterial compounds, as the bacteria are only disarmed and not killed ([@B2]). The efficacy of anti-biofilm enzymes has been proven with DispersinB^®^ for the treatment of infectious diseases in a chronic wound mouse model of MRSA infection ([@B20]), and in the reduction of colonization of catheters by *S. aureus* ([@B12]). The removal of capsular polysaccharide by the phage-encoded enzyme endosialidase E reduces the virulence of *E. coli* K1 in a non-invasive model in neonatal rats ([@B44]). Similarly, depolymerase enzymes encoded by phages infecting *Erwinia amylovora* have been proposed in the control of plant diseases ([@B36]). In addition, the removal of polymeric extracellular material might improve the action of antibiotics against bacteria forming biofilms, since physical interference could be avoided ([@B17]; [@B1]).

This study supports that phages possess structural components such as the novel EPS depolymerase (Dpo7) that inhibit biofilm formation and disperses preformed biofilms of *S. epidermidis* and *S. aureus*. These kinds of proteins might constitute a new approach to remove biofilms, thus improving the treatment of biofilm-associated recalcitrant infections.
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